SETD2 and endometrial carcinoma: Therefore, these results indicate that ICI treatment rather than chemotherapy or target therapy may be more suitable for endometrial carcinoma, colorectal adenocarcinoma, and stomach adenocarcinoma patients with SETD2 mutations.